| Nonalcoholic fatty liver disease and diabetes are associated with decreased CYP3A4 protein expression and activity in human liver R Jamwal, SM De La Monte, K Ogasawara, S Adusumalli, BB Barlock, ... Molecular pharmaceutics 15 (7), 2621-2632, 2018 | 109 | 2018 |
| Multiplex and label-free relative quantification approach for studying protein abundance of drug metabolizing enzymes in human liver microsomes using SWATH-MS R Jamwal, BJ Barlock, S Adusumalli, K Ogasawara, BL Simons, ... Journal of proteome research 16 (11), 4134-4143, 2017 | 53 | 2017 |
| Characterization of byproducts from chemical syntheses of oligonucleotides containing 1-methyladenine and 3-methylcytosine Q Tang, A Cai, K Bian, F Chen, JC Delaney, S Adusumalli, AC Bach, ... ACS omega 2 (11), 8205-8212, 2017 | 16 | 2017 |
| Role of molybdenum-containing enzymes in the biotransformation of the novel ghrelin receptor inverse agonist PF-5190457: a reverse translational bed-to-bench approach S Adusumalli, R Jamwal, RS Obach, TF Ryder, L Leggio, F Akhlaghi Drug Metabolism and Disposition 47 (8), 874-882, 2019 | 13 | 2019 |
| Initial pharmacological characterization of a major hydroxy metabolite of PF-5190457: inverse agonist activity of PF-6870961 at the ghrelin receptor SL Deschaine, MA Hedegaard, CL Pince, M Farokhnia, JE Moose, ... Journal of Pharmacology and Experimental Therapeutics 386 (2), 117-128, 2023 | 5 | 2023 |
| Development and validation of an assay for a novel ghrelin receptor inverse agonist PF-5190457 and its major hydroxy metabolite (PF-6870961) by LC-MS/MS in human plasma S Adusumalli, R Jamwal, L Leggio, F Akhlaghi Journal of Chromatography B 1130, 121820, 2019 | 4 | 2019 |
